Claim Missing Document
Check
Articles

Found 3 Documents
Search

Faktor-Faktor yang Memengaruhi Clinical Outcome Nyeri pada Pasien Diabetes Neuropati di Poliklinik Penyakit Dalam RSUD Kota Yogyakarta Dirga, Dirga; Nugroho, Agung Endro; Pramantara, Dewa Putu
Jurnal Kefarmasian Indonesia VOLUME 9, NOMOR 2, AGUSTUS 2019
Publisher : Pusat Penelitian dan Pengembangan Biomedis dan Teknologi Dasar Kesehatan

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.22435/jki.v9i2.388

Abstract

The treatment of diabetic neuropathy pain has not possessed an explicit guideline therapy yet, due to the difference perception towards the respond of pain from certain individu. In indonesia, the data regarding factors that could affect clinical outcome of pain are still limited to the meassurement of tolerance, perception, and sensitivity of certain pain. This study aims to describe the clinical outcome of pain along with the affected factors for diabetic neuropathy patients in Internal Medicine Clinics of Yogyakarta City General Hospital. The design of this This study is an analytical descriptive with cross sectional approach to 81 patients of diabetic neuropathy pain. The pain level measurement of patient is conducted with Visual Analog Scale (VAS) Instrument. The obtained data are analyzed statistically by applying Chi Square and logistical regression analysis. The results of this study showed that 60 patients (74,07%) had reached clinical outcome of pain, and 21 patients (25,93%) had not reached clinical outcome of pain. Factors that affecting clinical outcome of pain to diabetic neuropathy patients were BMI non-obesity (p = 0.043), period of diabetic less than 5 year (p = 0.022), anticonvulsant consuming (p = 0.039), and neurotropic vitamin (p = 0.002). According to the result of multivariate analysis by applying logistical regression test, neurotropic vitamin was claimed as the most influential factor towards clinical outcome of neuropathy pain to diabetic neuropathy patients with p = 0.013, OR = 11.109, and Cl = (1,668-73,970).
Comparison of Clinical Outcomes Between Acetylcysteine and Ambroxol in Post Acute Exacerbation of COPD Patients Molidia, Sri Rahmat; Pramantara, Dewa Putu; Ikawati, Zullies
JSFK (Jurnal Sains Farmasi & Klinis) Vol 11 No 1 (2024): J Sains Farm Klin 11(1), April 2024
Publisher : Fakultas Farmasi Universitas Andalas

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.25077/jsfk.11.1.58-66.2024

Abstract

Literature studies show that the use of acetylcysteine or ambroxol can accelerate improvement of clinical outcomes of post acute exacerbation chronic obstructive pulmonary disease (AECOPD) patients. This study aims to compare the clinical outcomes of acetylcysteine and ambroxol administration in post AECOPD patients. The study was cohort design, prospective, to comparison of clinical outcomes of acetylcysteine and ambroxol with post AECOPD outpatients coming for clinical chekups in August 2023 at Respira Lung Hospital Yogyakarta. Clinical outcomes parameters were observed on day zero and thirty for CAT score and day zero and four for cough score. The patients were categorized into two groups: acetylcysteine group (n=30) and ambroxol group (n=30). There was no significant difference between two groups to change of CAT score and cough score (p>0.05) post AECOPD. The acetylcysteine group compared to ambroxol, there was a mean decrease in morning cough score -1.10±1.11 vs -0.87±1.12 (p=0.228), night cough score -1.53±1.43 vs -1.13±1.31 (p=0.438), and CAT score -2.43±5.45 vs -2.90±3.41 (p=0.391). Providing additional therapy of acetylcysteine or ambroxol in this study did not significantly reduce cough scores and CAT scores in post AECOPD patients.
Kajian Literatur: Efektivitas Asetilsistein Dosis Tinggi Pada Pasien PPOK Molidia, Sri Rahmat; Pramantara, Dewa Putu; Ikawati, Zullies
Majalah Farmaseutik Vol 21, No 3 (2025)
Publisher : Faculty of Pharmacy, Universitas Gadjah Mada

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.22146/farmaseutik.v21i3.93852

Abstract

Penyakit paru obstruktif kronik (PPOK) merupakan penyebab utama mortalitas dan morbiditas di seluruh dunia, ditandai dengan keterbatasan aliran udara yang persisten, hipersekresi mukus, stres oksidatif, dan inflamasi saluran napas. Asetilsistein memiliki sifat antioksidan dan antiinflamasi, yang telah menunjukkan manfaat bergantung pada dosisnya. Review ini menilai efektivitas dosis tinggi dari asetilsisitein pada pasien PPOK dalam memperbaiki luaran klinis dan frekuensi eksaserbasi. Studi Randomized Control Trial (RCT) dilibatkan dalam kajian literatur ini mengikuti daftar checklist PRISMA. Hasil review dari 6 RCT menunjukkan bahwa pemberian asetilsistein dosis tinggi (>400 mg perhari) secara signifikan dapat menurunkan frekuensi eksaserbasi, memperbaiki fungsi paru (FEV1, FVC, FEV/FVC), perubahan biomarker oksidasi dan inflamasi (Malondialdehid, Glutation, Glutation Peroksida, Cystein, C-Reactive protein). Kesimpulan dari penambahan terapi asetilsistein dosis tinggi mampu menurunkan frekuensi eksaserbasi dan perbaikan klinis secara signifikan dibandingkan plasebo